Literature DB >> 16823853

Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China.

Meng Hua Tao1, Wang Hong Xu, Wei Zheng, Zuo-Feng Zhang, Yu-Tang Gao, Zhi Xian Ruan, Jia Rong Cheng, Jing Gao, Yong Bing Xiang, Xiao Ou Shu.   

Abstract

Oral contraceptive (OC) and intrauterine device (IUD) use have been shown to be protective factors for endometrial cancer in several epidemiological studies; however, few studies have been conducted in Chinese populations. We evaluated the association between OC and IUD use and endometrial cancer risk in a population-based case-control study among Chinese women in Shanghai, China. The study included 1,204 newly diagnosed endometrial cancer cases and 1,212 age frequency-matched healthy controls. Logistic regression models were used to estimate adjusted odds ratios (OR) and their 95% confidence intervals (95% CI). In our study population, 18.5% cases and 24.9% controls reported having ever used OCs with an OR of 0.75 (95% CI, 0.60-0.93), after adjusting for known risk or protective factors for endometrial cancer. The risk of endometrial cancer decreased with long-term use of OCs with the OR for more than 72 months of use being 0.50 (95% CI, 0.30-0.85). The effect of OC use remained 25 or more years after cessation of use; the associated OR was 0.57 (95% CI = 0.42-0.78) as compared to nonusers. Similarly, fewer cases than controls had ever used IUD, with the multivariable adjusted OR being 0.53 (95% CI = 0.43-0.65). A reduction in risk was observed regardless the duration of use or age at first and last use. These results suggest that OC and IUD use may confer long-term protection against endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823853     DOI: 10.1002/ijc.22081

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

2.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

Authors:  Tsogzolmaa Dorjgochoo; Xiao-Ou Shu; Hong-Lan Li; Han-Zhu Qian; Gong Yang; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

3.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

4.  Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women.

Authors:  Todd R Sponholtz; Julie R Palmer; Lynn A Rosenberg; Elizabeth E Hatch; Lucile L Adams-Campbell; Lauren A Wise
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-02-23       Impact factor: 4.254

Review 5.  Copper containing intra-uterine devices versus depot progestogens for contraception.

Authors:  G Justus Hofmeyr; Mandisa Singata; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 6.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

7.  Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

Authors:  Ashley S Felix; Mia M Gaudet; Carlo La Vecchia; Christina M Nagle; Xiao Ou Shu; Elisabete Weiderpass; Hans Olov Adami; Shirley Beresford; Leslie Bernstein; Chu Chen; Linda S Cook; Immaculata De Vivo; Jennifer A Doherty; Christine M Friedenreich; Susan M Gapstur; Dierdre Hill; Pamela L Horn-Ross; James V Lacey; Fabio Levi; Xiaolin Liang; Lingeng Lu; Anthony Magliocco; Susan E McCann; Eva Negri; Sara H Olson; Julie R Palmer; Alpa V Patel; Stacey Petruzella; Jennifer Prescott; Harvey A Risch; Lynn Rosenberg; Mark E Sherman; Amanda B Spurdle; Penelope M Webb; Lauren A Wise; Yong-Bing Xiang; Wanghong Xu; Hannah P Yang; Herbert Yu; Anne Zeleniuch-Jacquotte; Louise A Brinton
Journal:  Int J Cancer       Date:  2014-09-30       Impact factor: 7.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.